High EPHA4 levels have been reported to contribute to the initiation of breast cancer [32], facilitate the acquisition of cisplatin-resistant properties in well-differentiated cervical cancer cells [33], and promote the migration and invasiveness of clear cell renal cell carcinoma and pancreatic ductal adenocarcinoma [34,35]. Here, EPHA4 is linked to breast cancer.